BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging' TumorGlobeNewsWire • 06/02/21
BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D DirectorGlobeNewsWire • 05/11/21
BriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview with SmallCapVoice.comGlobeNewsWire • 04/21/21
BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 MillionGlobeNewsWire • 04/12/21
BriaCell Stock Is Trading Higher After Encouraging Bria-IMT Data At AACR Annual MeetingBenzinga • 04/12/21
BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021GlobeNewsWire • 04/12/21
BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021GlobeNewsWire • 03/30/21
BriaCell Announces Pricing of US$25 Million Public Offering and Nasdaq ListingGlobeNewsWire • 02/24/21
BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell TherapiesGlobeNewsWire • 01/12/21